Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler
TipRanksApr 9 07:06 ET
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
TipRanksMar 19 08:11 ET
Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)
TipRanksMar 15 05:17 ET
Promising Clinical Progress and Strategic Milestones Bolster Buy Rating for Monte Rosa Therapeutics
TipRanksMar 14 16:45 ET
Monte Rosa Therapeutics (GLUE) Receives a Buy From Piper Sandler
TipRanksMar 12 06:36 ET
Monte Rosa Therapeutics Analyst Ratings
BenzingaFeb 15 08:32 ET
Analysts' Opinions Are Mixed on These Healthcare Stocks: Celldex (CLDX), Monte Rosa Therapeutics (GLUE) and Solid Biosciences (SLDB)
TipRanksNov 14, 2023 03:40 ET
Analysts Offer Insights on Healthcare Companies: Vertex (VERX) and Monte Rosa Therapeutics (GLUE)
TipRanksNov 9, 2023 15:21 ET
JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $11
BenzingaOct 19, 2023 15:08 ET
Monte Rosa Therapeutics Analyst Ratings
BenzingaOct 19, 2023 15:07 ET
Hold Rating on Monte Rosa Therapeutics Due to Clinical Uncertainties and Delayed Launch of MRT-2359: An Analysis
TipRanksOct 19, 2023 08:17 ET
Monte Rosa Therapeutics Analyst Ratings
BenzingaAug 11, 2023 09:11 ET
Berenberg Bank Reaffirms Their Buy Rating on Monte Rosa Therapeutics (GLUE)
TipRanksMay 15, 2023 10:35 ET
Monte Rosa Therapeutics (GLUE) Gets a Hold From SVB Securities
TipRanksMay 15, 2023 06:06 ET
Piper Sandler Remains a Buy on Monte Rosa Therapeutics (GLUE)
TipRanksMay 12, 2023 08:15 ET
SVB Securities Sticks to Their Hold Rating for Monte Rosa Therapeutics (GLUE)
TipRanksMar 20, 2023 10:08 ET
Credit Suisse Maintains Neutral on Monte Rosa Therapeutics, Lowers Price Target to $11
BenzingaMar 17, 2023 10:42 ET
Analysts Are Bullish on Top Healthcare Stocks: Morphosys Ag (MOR), Monte Rosa Therapeutics (GLUE)
TipRanksMar 16, 2023 15:26 ET
Monte Rosa Therapeutics Analyst Ratings
Benzinga Analyst RatingsJan 3, 2023 04:37 ET
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Announces $19 Price Target
Benzinga Real-time NewsJan 3, 2023 04:37 ET
No Data
No Data